Shionogi, GSK Three-Drug HIV Treatment Outperforms Gilead's Atripla
This article was originally published in PharmAsia News
Executive Summary
Shionogi and GlaxoSmithKline said their three-drug treatment for HIV performed better than Gilead Science's Atripla in a Phase III trial.